These findings provide the proof of concept for evaluating BsAb-targeting TSLPR as a potential therapy for improving the outcome for patients with CRLF2/TSLPR-overexpressing Ph-like B-ALL. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.